Evidence-based approach of the use of Botulinum toxin type A (BTX) in cerebral palsy.
A systematic review with the Sachett model of evidence-based medicine of the use of Botulinum toxin type A (BTX) for intervention in children with Cerebral Palsy (CP) is highlighted. Currently, the evidence showed that BTX is useful for treating pes equinus due to spasticity of the gastrocnemius-soleus muscles. However, careful patient selection and goals of treatment have to be addressed. More multi-centre clinical trials with standardized protocols are needed before widespread recommendation of the use of BTX in treating spasticity in CP can be made.
Wong
Virginia
V
Division of Neurodevelopmental Paediatrics, Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, P.R. China. vcnwong@hkucc.hku.hk
D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D002547:Cerebral Palsy / Q000188:drug therapy*; D019317:Evidence-Based Medicine; D006801:Humans; D009465:Neuromuscular Agents / Q000627:therapeutic use*
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A